ALX Oncology Holdings Inc. Profile Avatar - Palmy Investing

ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatm…

Biotechnology
US, South San Francisco [HQ]

Government Awards Analysis Beta

Obligations Over-Time

Awards
Obligations

ALX Oncology Holdings Inc. has no obligation with a government/award agency.

Latest Obligations

Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
vs. Previous FY
Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0

Spending By Type

Awards
Obligations

ALX Oncology Holdings Inc. can't present spending by time.

Get PRO Today

With PRO you will unlock all insights related to government awards of ALX Oncology Holdings Inc..

End of ALXO's Analysis
CIK: 1810182 CUSIP: 00166B105 ISIN: US00166B1052 LEI: - UEI: -
Secondary Listings
ALXO has no secondary listings inside our databases.